Dr Joe Keegan is a respected international business leader with a successful track record spanning 30 years in the life-sciences industry. Joe led ForteBio as CEO through a Series C financing and guided the company through a period of rapid sales growth from sub-$5m to $27m that culminated in the company’s sale to Pall Corporation, delivering a return of $160m to investors. Prior to his tenure at ForteBio, Joe served as CEO of NASDAQ-listed Molecular Devices Corporation, where he grew revenues from $25m to $185m and oversaw the company’s acquisition by MDS Corporation for $615m. He currently serves on the Boards of Bio-Techne Corporation (NASDAQ:TECH) and Interpace Biosciences (OTCMKTS:IDXG) and a number of early- and growth-stage companies including Chairman roles at ArrayJet, Carterra and HaloLabs. Joe’s other past appointments include two-time Chairman of the Analytical, Life Science & Diagnostics Association (ALDA) and the San Francisco Opera board of directors. .